Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier and get daily trading ideas and historical data downloads. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or

Aim Immunotech Inc (AIM)

Aim Immunotech Inc (AIM)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE Arca]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE Arca]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 8,436
  • Shares Outstanding, K 68,754
  • Annual Sales, $ 200 K
  • Annual Income, $ -28,960 K
  • EBIT $ -28 M
  • EBITDA $ -28 M
  • 60-Month Beta 0.41
  • Price/Sales 35.74
  • Price/Cash Flow N/A
  • Price/Book 2.58
  • Price/Earnings ttm 0.00
  • Earnings Per Share ttm -0.47
  • Most Recent Earnings $-0.06 on 11/14/24
  • Next Earnings Date 04/04/25 [--]
  • Annual Dividend & Yield N/A (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sector Medical
  • INDUSTRY GROUPING Medical - Drugs

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 2 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/24
See More
  • Average Estimate -0.09
  • Number of Estimates 1
  • High Estimate -0.09
  • Low Estimate -0.09
  • Prior Year -0.26
  • Growth Rate Est. (year over year) +65.38%

Price Performance

See More
Period Period Low Period High Performance
1-Month
0.1105 +17.65%
on 02/25/25
0.1588 -18.14%
on 02/26/25
-0.0128 (-8.96%)
since 02/20/25
3-Month
0.1105 +17.65%
on 02/25/25
0.2540 -48.82%
on 01/07/25
-0.0600 (-31.58%)
since 12/20/24
52-Week
0.1105 +17.65%
on 02/25/25
0.6200 -79.03%
on 04/11/24
-0.2701 (-67.51%)
since 03/20/24

Most Recent Stories

More News
AIM ImmunoTech Inc. Participates in the Virtual Investor “Top 5 for ‘25” On-Demand Conference

AIM : 0.1300 (+5.95%)
Virtual Investor Releases Next Wave of "Top 5 for '25" On-Demand Videos

- Access video webcasts from all participating companies here

AIM : 0.1300 (+5.95%)
SONN : 1.4300 (+2.14%)
MBRX : 1.0900 (+4.81%)
AIM ImmunoTech, PepGen, Aeon, Tiziana, Moleculin: 5 Biotech Stocks That Led Retail Message Growth Last Week

New trial data, a reverse split, and financing moves triggered a spike in retail chatter for these biotech stocks in the week ending Feb. 28, 2025.

TLSA : 1.2900 (-6.86%)
AIM : 0.1300 (+5.95%)
PEPG : 1.89 (-6.68%)
AEON : 0.7250 (-3.33%)
MBRX : 1.0900 (+4.81%)
AIM announces Paul Goepfert, MD, as the principal investigator for the planned clinical study of Ampligen and FluMist as a vaccine for avian influenza

AIM : 0.1300 (+5.95%)
AIM ImmunoTech Announces NYSE American Acceptance of Plan to Regain Listing Compliance

AIM : 0.1300 (+5.95%)
AIM ImmunoTech Appoints David Chemerow to Board of Directors as an Independent Director

AIM : 0.1300 (+5.95%)
AIM Doses First New Subject in Phase 2 Study of Ampligen and Imfinzi as a Potential Combination Therapy for Late-Stage Pancreatic Cancer

AIM : 0.1300 (+5.95%)
AIM ImmunoTech Releases Virtual Investor “What This Means Segment”

AIM : 0.1300 (+5.95%)
AIM ImmunoTech announces that it will not proceed with an offering pursuant to its Registration Statement on Form S-1 until after it files its Annual Report on Form 10-K for the fiscal year ended December 31, 2024

AIM : 0.1300 (+5.95%)
AIM ImmunoTech announces a planned follow-up clinical study evaluating a combination treatment of AIM’s Ampligen® and AstraZeneca’s FluMist® to address the recent avian influenza outbreaks

AIM : 0.1300 (+5.95%)

Business Summary

AIM ImmunoTech Inc. is an immuno-pharma company. It is focused on the research and development of therapeutics to treat multiple types of cancers and immune-deficiency diseases. The company's flagship products include Ampligen(R), Rintamod(R) and Alferon N Injection(R) which are in clinical stage. AIM...

See More

Key Turning Points

3rd Resistance Point 0.1487
2nd Resistance Point 0.1393
1st Resistance Point 0.1347
Last Price 0.1300
1st Support Level 0.1207
2nd Support Level 0.1113
3rd Support Level 0.1067

See More

52-Week High 0.6200
Fibonacci 61.8% 0.4254
Fibonacci 50% 0.3652
Fibonacci 38.2% 0.3051
Last Price 0.1300
52-Week Low 0.1105

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar